RA: Background Dose Doesn't Matter With JAK Inhibitor (CME/CE)

(MedPage Today) -- Efficacy seen whether methotrexate dose was low or high with Xeljanz
via RA: Background Dose Doesn't Matter With JAK Inhibitor (CME/CE)
by